These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Hurkmans CW; Cuijpers JP; Lagerwaard FJ; Widder J; van der Heide UA; Schuring D; Senan S Radiat Oncol; 2009 Jan; 4():1. PubMed ID: 19138400 [TBL] [Abstract][Full Text] [Related]
10. No consensus on the optimal palliative radiotherapy regimen for people with inoperable non-small-cell lung cancer. Baldini E Cancer Treat Rev; 2003 Oct; 29(5):445-7. PubMed ID: 12972363 [No Abstract] [Full Text] [Related]
11. [Stereotactic Body Radiotherapy for Centrally Located Non-small Cell Lung Cancer]. Wan Y; Huang J; Xu F Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):413-418. PubMed ID: 29764593 [TBL] [Abstract][Full Text] [Related]
12. Radiation therapy for non-small cell lung cancer (NSCLC). Choy H; Chakravarthy A; Kim JS Cancer Treat Res; 2001; 105():121-48. PubMed ID: 11224985 [No Abstract] [Full Text] [Related]
13. Five-year Long-term Outcomes of Stereotactic Body Radiation Therapy for Operable Versus Medically Inoperable Stage I Non-small-cell Lung Cancer: Analysis by Operability, Fractionation Regimen, Tumor Size, and Tumor Location. Schonewolf CA; Heskel M; Doucette A; Singhal S; Frick MA; Xanthopoulos EP; Corradetti MN; Friedberg JS; Pechet TT; Christodouleas JP; Levin W; Berman A; Cengel KA; Verma V; Hahn SM; Kucharczuk JC; Rengan R; Simone CB Clin Lung Cancer; 2019 Jan; 20(1):e63-e71. PubMed ID: 30337269 [TBL] [Abstract][Full Text] [Related]
14. Absence of toxicity with hypofractionated 3-dimensional radiation therapy for inoperable, early stage non-small cell lung cancer. Faria SL; Souhami L; Portelance L; Duclos M; Vuong T; Small D; Freeman CR Radiat Oncol; 2006 Nov; 1():42. PubMed ID: 17078878 [TBL] [Abstract][Full Text] [Related]
15. Continuous hyperfractionated accelerated radiotherapy (CHART) and non-conventionally fractionated radiotherapy in the treatment of non-small cell lung cancer: a review and consideration of future directions. Hatton MQ; Martin JE Clin Oncol (R Coll Radiol); 2010 Jun; 22(5):356-64. PubMed ID: 20399629 [TBL] [Abstract][Full Text] [Related]
16. Quality of life assessment in advanced non-small-cell lung cancer patients undergoing an accelerated radiotherapy regimen: report of ECOG study 4593. Eastern Cooperative Oncology Group. Auchter RM; Scholtens D; Adak S; Wagner H; Cella DF; Mehta MP Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1199-206. PubMed ID: 11483329 [TBL] [Abstract][Full Text] [Related]
18. Response on behalf of the UK Stereotactic Body Radiotherapy Consortium to Brock et al. Clin Oncol (R Coll Radiol) 2008;20(9):666-676. Franks KN; Jain P; Dahele M; Peedell C; Hatton MQ; Faivre-Finn C Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):731-2. PubMed ID: 19717290 [No Abstract] [Full Text] [Related]
19. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up. Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929 [TBL] [Abstract][Full Text] [Related]
20. Lung stereotactic body radiation therapy for elderly patients aged ≥ 80 years with pathologically proven early-stage non-small cell lung cancer: a retrospective cohort study. Watanabe K; Katsui K; Sugiyama S; Yoshio K; Kuroda M; Hiraki T; Kiura K; Maeda Y; Toyooka S; Kanazawa S Radiat Oncol; 2021 Feb; 16(1):39. PubMed ID: 33622369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]